Direction on the EU Directive

Posted:
20
July 2004

As you are aware the EU Clinical Trials Directive has become part of the UK's regulatory and legal landscape from 1 May, 2004. Richmond Pharmacology has welcomed the directive which will help to harmonise trial standards across the board.We support the MHRA (Medicines and Healthcare products Regulatory Agency) which regulates implementation of the Directive, and we applaud our industry partners who have ensured that the implementation does not slow down or hinder the competitiveness of the UK's clinical research industry.This guide has been put together following numerous client requests for more information and greater clarity on how the directive will impact on research projects, timelines and approval systems.Direction on the Directive

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more